An investigation carried out in Seville evidence larelacion between the metabolic syndrome (MS) and cancer associated venous thromboembolic disease.

-some previous studies had already suggested this link, but for the ETV of unknown cause (idiopathic), it had not studied so much for cancer-related (neoplastic)

– in a sample of 113 patients with ETV, the prevalence of metabolic syndrome was 47%, no significant differences between both groups (45.5% in idiopathic) and 50% in neoplastic

– it is also the first work which has assessed the metabolic syndrome as a predictive factor in the evolution of the ETV

Seville, March of 2013.- specialists of the Hospital Virgen del Rocío and the Institute of Biomedicine of Seville are present in Badajozin the 39 th Congress of Neumosur, the results of an investigation that has succeeded in establishing the relationship between metabolic syndrome (MS) and venous thromboembolism associated with cancer, show a high prevalence of Ms among patients with VTE associated with neoplasia.

The metabolic syndrome (MS) is defined as a set of interrelated risk factors that identify people with an increased risk of cardiovascular disease. For his part, disease venous thromboembolic (VTE) includes deep vein thrombosis (DVT) and pulmonary thromboembolism (TEP) and is an important cause of morbidity and hospital mortality, as well as a large public health problem, affecting millions of people to the world. The causes of ETV can be varied, approximately between 20-30% of the patients is associated with cancer; in other cases the cause is unknown, called idiopathic.

So far, some previous studies had suggested an association between metabolic syndrome (SM) and venous thromboembolic disease (VTE). However, these studies were based mostly on patients with VTE idiopathic, without compare results with patients with neoplastic ETV, and none of them had not evaluated the SM as a predictive factor in the evolution of the ETV.

The study carried out in Seville first enters this field of research, studying this 133 patients with ETV, of whom 97 had venous thrombosis deep, 19 embolism of lung and 17 both pathologies, being ETV idiopathic in 106 patients and secondary to malignancy in 27. The research showed that the prevalence of MS in these patients was 47%, no highlight significant differences between both groups (45.5% in idiopathic. and 50% on neoplastic In addition, it showed that SM was not associated with any event of poor prognosis or with a set of all of them.

On the ETV

Venous thromboembolism is a set of changes that include deep venous thrombosis and embolism of lung. Venous thrombosis is the obstruction of the light of the vein by a thrombus. If it is big and sits in the deep veins of the legs (deep vein thrombosis) can break small fragments and obstruct blood flow in the lungs as they Ascend, giving rise to lung embolism.

The ETV is a serious health problem that affects approximately one in 1,000 people and up to 0.5% in people over 80 years. Observational studies have shown that the absolute risk of deep vein thrombosis is 10-20% in medical patients, and 40-80% in patients undergoing orthopedic surgery of the hip and knee and polytraumatized who have not received any preventive treatment. Recent data in Spain show an incidence of VTE of 103 cases per every 100,000 inhabitants/year.

The risk of VTE of each patient depends on individual factors (hereditary and acquired) and the risk associated with the disease, surgical procedure or other causes of reduced mobility as polytraumatized, pregnancies, long-lasting travel. One of the most important causes of ETV acquired is a cancer.

39Th Congress Neumosur

The results of this research will be shown in the 39 th Nemosur Congress, which will bring together more than 300 specialists from next March 14 in Badajoz for putting together the latest advances in treatment of respiratory diseases, which are the third leading cause of death in Spain, and debate about the most effective strategies to prevent its advance. During the Congress, which this year will also include the presence of Latin American professionals, in addition to pulmonologists Andalusia and Extremadura, research and results are treated on mechanical ventilation, pulmonary hypertension, palliative care in patients with COPD and thoracic injuries, inter alia